{"version":"1.0","type":"link","title":"Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.","author_name":"Pons-Fuster E 외","author_url":"https://prs-insight.online/author/Pons-Fuster%20E","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/134342","thumbnail_width":1200,"thumbnail_height":630}